[The evolution of a luminal breast cancer to a triple-negative and its impact on disease control with sacituzumab govitecan.]

Q3 Medicine Recenti progressi in medicina Pub Date : 2024-10-01 DOI:10.1701/4357.43479
Federica Cicchiello, Francesca Riva, Francesca Corti, Claudia Maggioni
{"title":"[The evolution of a luminal breast cancer to a triple-negative and its impact on disease control with sacituzumab govitecan.]","authors":"Federica Cicchiello, Francesca Riva, Francesca Corti, Claudia Maggioni","doi":"10.1701/4357.43479","DOIUrl":null,"url":null,"abstract":"<p><p>Triple negative breast cancer (TNBC) represents 15% of invasive breast cancer cases and is an aggressive subtype. Patients with metastatic TNBC have a poor prognosis. Efforts have been made to develop new therapeutic options and identify molecular biomarkers to improve overall survival and quality of life for TNBC patients. Immunotherapy has shown promising frontline clinical activity. To determine which patients will derive the most benefit from a combination of immune checkpoint inhibitors and chemotherapy in metastatic disease, it is essential to evaluate PD-L1 expression. Approximately 15% of TNBC patients have a germline mutation in BRCA1 and/or BRCA2, and for these patients, innovative therapeutic options such as olaparib and talazoparib, which are PARP inhibitors, are available. Sacituzumab govitecan (SG) is a humanized monoclonal antibody-drug conjugate directed against the surface antigen of human trophoblastic cells (Trop-2) expressed in approximately 90% of TNBC, coupled with SN-38, the active metabolite of irinotecan, a topoisomerase I inhibitor. Here, we present the case of a woman who was initially diagnosed with localized luminal B breast cancer (ER-positive; HER2-negative) and was treated with curative therapy. However, she later experienced a recurrence with metastatic TNBC (ER-negative/HER2-negative) and received treatment with sacituzumab govitecan, which resulted in prolonged disease control.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 10","pages":"52e-56e"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recenti progressi in medicina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1701/4357.43479","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Triple negative breast cancer (TNBC) represents 15% of invasive breast cancer cases and is an aggressive subtype. Patients with metastatic TNBC have a poor prognosis. Efforts have been made to develop new therapeutic options and identify molecular biomarkers to improve overall survival and quality of life for TNBC patients. Immunotherapy has shown promising frontline clinical activity. To determine which patients will derive the most benefit from a combination of immune checkpoint inhibitors and chemotherapy in metastatic disease, it is essential to evaluate PD-L1 expression. Approximately 15% of TNBC patients have a germline mutation in BRCA1 and/or BRCA2, and for these patients, innovative therapeutic options such as olaparib and talazoparib, which are PARP inhibitors, are available. Sacituzumab govitecan (SG) is a humanized monoclonal antibody-drug conjugate directed against the surface antigen of human trophoblastic cells (Trop-2) expressed in approximately 90% of TNBC, coupled with SN-38, the active metabolite of irinotecan, a topoisomerase I inhibitor. Here, we present the case of a woman who was initially diagnosed with localized luminal B breast cancer (ER-positive; HER2-negative) and was treated with curative therapy. However, she later experienced a recurrence with metastatic TNBC (ER-negative/HER2-negative) and received treatment with sacituzumab govitecan, which resulted in prolonged disease control.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[腔隙性乳腺癌向三阴性乳腺癌的演变及其对萨库珠单抗-戈维替康治疗疾病控制效果的影响]
三阴性乳腺癌(TNBC)占侵袭性乳腺癌病例的 15%,是一种侵袭性亚型。转移性 TNBC 患者预后较差。人们一直在努力开发新的治疗方案并确定分子生物标记物,以改善 TNBC 患者的总体生存期和生活质量。免疫疗法已显示出良好的一线临床活性。为了确定哪些患者能从免疫检查点抑制剂和化疗联合治疗转移性疾病中获益最多,必须对 PD-L1 的表达进行评估。大约15%的TNBC患者存在BRCA1和/或BRCA2的种系突变,对于这些患者,可以选择创新的治疗方案,如作为PARP抑制剂的奥拉帕利(olaparib)和他拉唑帕利(talazoparib)。萨妥珠单抗-戈维替康(SG)是一种针对人滋养细胞表面抗原(Trop-2)的人源化单克隆抗体-药物共轭物,Trop-2在大约90%的TNBC中都有表达,它与SN-38(一种拓扑异构酶I抑制剂伊立替康的活性代谢产物)结合使用。在此,我们介绍了一位女性患者的病例,她最初被诊断为局部管腔 B 型乳腺癌(ER 阳性;HER2 阴性),并接受了根治性治疗。然而,她后来又复发了转移性 TNBC(ER 阴性/HER2 阴性),并接受了萨希珠单抗戈维替康治疗,结果疾病得到了长期控制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Recenti progressi in medicina
Recenti progressi in medicina Medicine-Medicine (all)
CiteScore
0.90
自引率
0.00%
发文量
143
期刊介绍: Giunta ormai al sessantesimo anno, Recenti Progressi in Medicina continua a costituire un sicuro punto di riferimento ed uno strumento di lavoro fondamentale per l"ampliamento dell"orizzonte culturale del medico italiano. Recenti Progressi in Medicina è una rivista di medicina interna. Ciò significa il recupero di un"ottica globale e integrata, idonea ad evitare sia i particolarismi della informazione specialistica sia la frammentazione di quella generalista.
期刊最新文献
(Con)fine della salute: restituzione del lavoro di un ambulatorio popolare dai margini della città. [GLP-1 agonists reduce the risk of major cardiovascular events in older patients with type 2 diabetes, and SGLT2 inhibitors prevent hospitalizations for acute heart failure.] [Impact of Elon Musk's statements on the use of semaglutide in the Lazio Region: a time series analysis study.] [Effective treatment for Helicobacter pylori infection in adults: the 2024 American College of Gastroenterology guideline recommendations.] [Patients with heart failure experience fewer hospitalizations and reduced mortality when treated with mineralocorticoid receptor antagonists.]
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1